696 related articles for article (PubMed ID: 34026447)
1. Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.
Zhang W; Mehta A; Tong Z; Esser L; Voelcker NH
Adv Sci (Weinh); 2021 May; 8(10):2003937. PubMed ID: 34026447
[TBL] [Abstract][Full Text] [Related]
2. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.
Bangde P; Atale S; Dey A; Pandit A; Dandekar P; Jain R
Curr Gene Ther; 2017; 17(2):170-183. PubMed ID: 28494742
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
4. Folic Acid-Conjugated Brush Polymers Show Enhanced Blood-Brain Barrier Crossing in Static and Dynamic
Mazrad ZAI; Refaat A; Morrow JP; Voelcker NH; Nicolazzo JA; Leiske MN; Kempe K
ACS Biomater Sci Eng; 2024 May; 10(5):2894-2910. PubMed ID: 38556768
[TBL] [Abstract][Full Text] [Related]
5. Polymeric nanoparticles for drug delivery to the central nervous system.
Patel T; Zhou J; Piepmeier JM; Saltzman WM
Adv Drug Deliv Rev; 2012 May; 64(7):701-5. PubMed ID: 22210134
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
Saraiva C; Praça C; Ferreira R; Santos T; Ferreira L; Bernardino L
J Control Release; 2016 Aug; 235():34-47. PubMed ID: 27208862
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.
Ebrahimi Z; Talaei S; Aghamiri S; Goradel NH; Jafarpour A; Negahdari B
IET Nanobiotechnol; 2020 Aug; 14(6):441-448. PubMed ID: 32755952
[TBL] [Abstract][Full Text] [Related]
9. Receptor Targeted Polymeric Nanostructures Capable of Navigating across the Blood-Brain Barrier for Effective Delivery of Neural Therapeutics.
Dube T; Chibh S; Mishra J; Panda JJ
ACS Chem Neurosci; 2017 Oct; 8(10):2105-2117. PubMed ID: 28768412
[TBL] [Abstract][Full Text] [Related]
10. Treating Alzheimer's disease using nanoparticle-mediated drug delivery strategies/systems.
Roghani AK; Garcia RI; Roghani A; Reddy A; Khemka S; Reddy RP; Pattoor V; Jacob M; Reddy PH; Sehar U
Ageing Res Rev; 2024 Jun; 97():102291. PubMed ID: 38614367
[TBL] [Abstract][Full Text] [Related]
11. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
Fu L; Chung R; Shi B
Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
[TBL] [Abstract][Full Text] [Related]
12. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
Gidwani M; Singh AV
Curr Pharm Biotechnol; 2014; 14(14):1201-12. PubMed ID: 24809717
[TBL] [Abstract][Full Text] [Related]
14. Theranostic applications of nanoparticles in neurodegenerative disorders.
Ramanathan S; Archunan G; Sivakumar M; Tamil Selvan S; Fred AL; Kumar S; Gulyás B; Padmanabhan P
Int J Nanomedicine; 2018; 13():5561-5576. PubMed ID: 30271147
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system delivery of molecules across the blood-brain barrier.
Gosselet F; Loiola RA; Roig A; Rosell A; Culot M
Neurochem Int; 2021 Mar; 144():104952. PubMed ID: 33400964
[TBL] [Abstract][Full Text] [Related]
16. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
[TBL] [Abstract][Full Text] [Related]
17. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
18. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on Dual Targeting Delivery Systems for Brain Tumors.
Gao H
J Neuroimmune Pharmacol; 2017 Mar; 12(1):6-16. PubMed ID: 27270720
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
